108 related articles for article (PubMed ID: 1311929)
1. Enhanced RNase H activity with methylphosphonodiester/phosphodiester chimeric antisense oligodeoxynucleotides.
Giles RV; Tidd DM
Anticancer Drug Des; 1992 Feb; 7(1):37-48. PubMed ID: 1311929
[TBL] [Abstract][Full Text] [Related]
2. Chimeric oligodeoxynucleotide analogues: enhanced cell uptake of structures which direct ribonuclease H with high specificity.
Giles RV; Spiller DG; Tidd DM
Anticancer Drug Des; 1993 Feb; 8(1):33-51. PubMed ID: 8386514
[TBL] [Abstract][Full Text] [Related]
3. Increased specificity for antisense oligodeoxynucleotide targeting of RNA cleavage by RNase H using chimeric methylphosphonodiester/phosphodiester structures.
Giles RV; Tidd DM
Nucleic Acids Res; 1992 Feb; 20(4):763-70. PubMed ID: 1371864
[TBL] [Abstract][Full Text] [Related]
4. The uptake kinetics of chimeric oligodeoxynucleotide analogues in human leukaemia MOLT-4 cells.
Spiller DG; Tidd DM
Anticancer Drug Des; 1992 Apr; 7(2):115-29. PubMed ID: 1575885
[TBL] [Abstract][Full Text] [Related]
5. Antisense gene inhibition by C-5-substituted deoxyuridine-containing oligodeoxynucleotides.
Gutierrez AJ; Matteucci MD; Grant D; Matsumura S; Wagner RW; Froehler BC
Biochemistry; 1997 Jan; 36(4):743-8. PubMed ID: 9020771
[TBL] [Abstract][Full Text] [Related]
6. Phosphorothioate oligonucleotides block reverse transcription by the Rnase H activity associated with the HIV-1 polymerase.
Hatta T; Takai K; Yokoyama S; Nakashima H; Yamamoto N; Takaku H
Biochem Biophys Res Commun; 1995 Jun; 211(3):1041-6. PubMed ID: 7541196
[TBL] [Abstract][Full Text] [Related]
7. Binding affinity and specificity of Escherichia coli RNase H1: impact on the kinetics of catalysis of antisense oligonucleotide-RNA hybrids.
Lima WF; Crooke ST
Biochemistry; 1997 Jan; 36(2):390-8. PubMed ID: 9003192
[TBL] [Abstract][Full Text] [Related]
8. Induction of RNase H activity by Arabinose-peptide nucleic acid chimeras.
Pâtureau BM; Hudson RH; Damha MJ
Bioconjug Chem; 2007; 18(2):421-30. PubMed ID: 17373768
[TBL] [Abstract][Full Text] [Related]
9. Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology.
Gao WY; Han FS; Storm C; Egan W; Cheng YC
Mol Pharmacol; 1992 Feb; 41(2):223-9. PubMed ID: 1371582
[TBL] [Abstract][Full Text] [Related]
10. Phosphorothioate-phosphodiester oligonucleotide co-polymers: assessment for antisense application.
Ghosh MK; Ghosh K; Cohen JS
Anticancer Drug Des; 1993 Feb; 8(1):15-32. PubMed ID: 8386513
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of HIV-1 replication by a new type of circular dumbbell RNA/DNA chimeric oligonucleotides.
Park WS; Miyano-Kurosaki N; Abe T; Takai K; Yamamoto N; Takaku H
Biochem Biophys Res Commun; 2000 Apr; 270(3):953-60. PubMed ID: 10772932
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the RNase H cleavage kinetics and blood serum stability of the north-conformationally constrained and 2'-alkoxy modified oligonucleotides.
Honcharenko D; Barman J; Varghese OP; Chattopadhyaya J
Biochemistry; 2007 May; 46(19):5635-46. PubMed ID: 17411072
[TBL] [Abstract][Full Text] [Related]
13. RNase H1 can catalyze RNA/DNA hybrid formation and cleavage with stable hairpin or duplex DNA oligomers.
Li J; Wartell RM
Biochemistry; 1998 Apr; 37(15):5154-61. PubMed ID: 9548746
[TBL] [Abstract][Full Text] [Related]
14. Filling the gap in LNA antisense oligo gapmers: the effects of unlocked nucleic acid (UNA) and 4'-C-hydroxymethyl-DNA modifications on RNase H recruitment and efficacy of an LNA gapmer.
Fluiter K; Mook OR; Vreijling J; Langkjaer N; Højland T; Wengel J; Baas F
Mol Biosyst; 2009 Aug; 5(8):838-43. PubMed ID: 19603119
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and anti-influenza virus-A activity of circular dumbbell RNA DNA chimeric oligonucleotides.
Abe T; Hatta T; Yamakawa H; Takai K; Yokota T; Takaku H
Nucleic Acids Symp Ser; 1997; (37):219-20. PubMed ID: 9586078
[TBL] [Abstract][Full Text] [Related]
16. The influence of target protein half-life on the effectiveness of antisense oligonucleotide analog-mediated biologic responses.
Spiller DG; Giles RV; Broughton CM; Grzybowski J; Ruddell CJ; Tidd DM; Clark RE
Antisense Nucleic Acid Drug Dev; 1998 Aug; 8(4):281-93. PubMed ID: 9743466
[TBL] [Abstract][Full Text] [Related]
17. Potent and selective inhibition of gene expression by an antisense heptanucleotide.
Wagner RW; Matteucci MD; Grant D; Huang T; Froehler BC
Nat Biotechnol; 1996 Jul; 14(7):840-4. PubMed ID: 9631007
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of N-ras oncogene anti-sense, sense and nonsense sequence methylphosphonate oligonucleotide analogues.
Tidd DM; Hawley P; Warenius HM; Gibson I
Anticancer Drug Des; 1988 Aug; 3(2):117-27. PubMed ID: 2457379
[TBL] [Abstract][Full Text] [Related]
19. Selective binding of trisamine-modified phosphorothioate antisense DNA to target mRNA improves antisense activity and reduces toxicity.
Matsukura M; Okamoto T; Miike T; Sawai H; Shinozuka K
Biochem Biophys Res Commun; 2002 May; 293(5):1341-7. PubMed ID: 12054660
[TBL] [Abstract][Full Text] [Related]
20. Properties of nicked and circular dumbbell RNA/DNA chimeric oligonucleotides containing antisense phosphodiester oligodeoxynucleotides.
Yamakawa H; Abe T; Saito T; Takai K; Yamamoto N; Takaku H
Bioorg Med Chem; 1998 Jul; 6(7):1025-32. PubMed ID: 9730239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
